24/7 Market News Snapshot 10 June, 2025 – Vaxart, Inc Common Stock (NASDAQ:VXRT)

June 10, 2025

DENVER, Colo., 10 June, 2025 (www.247marketnews.com) – (NASDAQ:VXRT) are discussed in this article.
Today, Vaxart, Inc. (NASDAQ:VXRT) has captured significant market attention with its stock price surging 112.79%, climbing from an opening price of $0.396 to a current level of $0.845. The stock’s trading volume has reached 7.25 million shares, signaling robust investor confidence driven by recent positive developments related to the company’s innovative oral vaccines. This dramatic increase underscores the perceived growth potential of Vaxart, making it an appealing prospect for investors.

Coinciding with this remarkable stock performance, Vaxart has announced an upcoming release of topline data from its Phase I clinical trial targeting norovirus. The results are scheduled to be disclosed before the market opens on Wednesday, June 11, 2025. The anticipation surrounding this data is palpable, as stakeholders eagerly await insights into the efficacy and progress of Vaxart’s vaccine efforts.

In addition to the data release, Vaxart’s senior management will hold a live conference call at 8:30 a.m. Eastern Time on June 11, providing an opportunity to discuss trial outcomes, crucial updates on their pipeline, and future strategic directions. This event is positioned as a key moment for analysts and investors to better understand the transformative potential of Vaxart’s proprietary oral vaccine technology.

The company’s advancements are noteworthy, particularly its ability to develop orally administered vaccines that require no refrigeration, addressing significant logistical challenges associated with traditional vaccination methods. Vaxart’s innovative approach encompasses a diverse portfolio, including vaccine candidates for coronavirus, influenza, and therapeutic solutions for human papillomavirus (HPV).

With numerous patents filed to safeguard its unique technologies and methodologies, Vaxart is well-poised to emerge as a leader in the biotechnology sector. Interested parties are encouraged to participate in the upcoming call to engage directly with Vaxart’s leadership, as the company continues to redefine the future of vaccination.

Related news for (VXRT)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.